Human parainfluenza virus type 3 antigen (HPIV3 antigen)

Human parainfluenza virus type 3 (HPIV3) antigen refers to the structural and functional proteins of HPIV3, a significant human respiratory pathogen in the Paramyxoviridae family [3, 15, 17]. The most prominent antigens are the surface glycoproteins: Hemagglutinin-neuraminidase (HN) and the Fusion (F) protein [7, 12, 21]. HN mediates viral attachment to sialic acid receptors on the host cell surface and possesses neuraminidase activity to facilitate the release of progeny virions, while the F protein triggers the fusion of the viral envelope with the host cell membrane to allow entry [10, 13, 18]. Other important antigens include the Matrix (M) protein, which coordinates viral assembly, and the Nucleocapsid (N) protein [1, 17, 21]. HPIV3 is a leading cause of severe lower respiratory tract infections, such as bronchiolitis and pneumonia, particularly in infants, the elderly, and immunocompromised patients [15, 19, 20]. While no vaccines or specific antivirals are currently approved, therapeutic development focuses on neutralizing monoclonal antibodies (e.g., PI3-E12), small molecule inhibitors of HN or F (e.g., Zanamivir), and adoptive T-cell therapies targeting viral epitopes [8, 9, 11, 15]. These interventions aim to prevent viral entry, inhibit replication, or enhance the host's immune clearance of the virus.

Other names

HPIV-3 antigenHuman respirovirus 3 antigenHPIV3 viral proteinsParainfluenza virus 3 surface glycoproteinsHPIV3 HN and F proteins

Inhibition of viral attachment to host sialic acid receptors, blockade of viral-cell membrane fusion, inhibition of neuraminidase-mediated viral release, and antibody-mediated neutralization of viral particles.